Genentech/Roche's Lucentis and Eli Lilly's Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
Posted on: Monday, 24 September 2007, 09:00 CDT
WALTHAM, Mass., Sept. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that by 2016 Genentech/Roche's Lucentis and Eli Lilly's ruboxistaurin will drive the markets for the treatment of diabetic retinopathy and diabetic nephropathy.
The new Pharmacor report entitled Diabetic Complications: Retinopathy, Neuropathy, and Nephropathy finds that, over the next decade, treatment of diabetic complications will expand considerably beyond tight control of blood pressure and glucose levels. Lucentis and ruboxistaurin will come the closest to achieving blockbuster status as treatments for diabetic complications in the world's major pharmaceutical markets -- the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Additionally, although promising drug classes with potential disease-modifying activity that include PKC inhibitors and aldose reductase inhibitors have suffered a decade of setbacks and disappointing efficacy data, the report finds that longer-term market growth will be driven by several of these novel therapies.
Therapies for the painful symptoms of diabetic neuropathy will continue to dominate sales, and few patients suffering non-painful diabetic neuropathy will receive treatment until the launches of disease-modifying therapies near the midpoint of the 2006-2016 forecast period.
"The diabetic neuropathy market will experience growth during the second half of our study period because of increasing use of Pfizer's antiepileptic drug, Lyrica, and Eli Lilly's antidepressant Cymbalta, which are both approved specifically for the treatment of diabetic neuropathic pain," said Donny Wong, Ph.D., analyst at Decision Resources. "Longer term growth will also be driven by the launch of novel disease-modifying therapies such as Dainippon/Eisai/Kyorin's ranirestat and Sangamo Biosciences' SB-509."
About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources
CONTACT: Elizabeth Marshall, of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies for Drug Delivery Technologies Industry
- Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation
- The Effect of Drugs From Novartis and Sanofi-Aventis on Mortality Rates Will Drive Prescription Decisions in Hypertension Treatment
- MultiVu Video Feed: FDA Approves DORIBAX(TM) (Doripenem for Injection) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
- FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
- FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
- The Cancer Cure Coalition Supports the Nomination of Dr. Andrew Von Eschenbach As Commissioner of the U.S. FDA and Calls for the Approval of Advexin, a New Gene Therapy Treatment for Cancer
- Changing Customer Priorities to Boost IV Therapy and Enteral Nutrition Device Markets
- American Diabetes Association Survey Finds Most People With Diabetes Don't Know About Highly Prevalent, Serious Complication
- Research and Markets: Application Server Markets Expected to Reach $5.2 Billion By 2009
 |
 |
User Comments (0)
RSS Feeds